When a new marketing lead took over a biologics brand for a leading global pharmaceutical company, she knew something was amiss. The company’s reports showed the drug performed strongly in its primary market, but lagged far behind expectations in its secondary indication. She began asking questions:
How big was the true market?
Do we understand where we are successful and where we aren’t?
What can we do to sustain and increase growth?
And, why did it appear patients were dropping off due to cost-related factors when the company provided assistance programs?
To investigate, Navigant provided an objective, third-party analysis of the drug’s true market potential for the secondary indication.
Thank you for your interest in the report! Click below to get your copy.Download Now
Enter the 6 digit code sent to your mobile number
Click on Resend the verification code again